42 results about "Poxvirus Infections" patented technology

This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.

This invention provides methods for inhibiting or treating infection by viruses, in particular pox viruses by modulating a kinase, in particular by inhibiting a host cell kinase, involved in mediating viral infection. Methods to identify, validate, and classify the cellular proteins required by viruses during infection of host cells in order to select agents which can inhibit viral infection are described herein. Using a systems biology approach the virus/host cell interaction is studied from initial attachment of the incoming virus to the cell surface, to entry, transcription, replication, biosynthesis, and assembly of progeny particles. The method employs a siRNA screening platform and uses gene silencing to map the ‘viral infectome’—a compilation of cellular proteins that the virus needs to establish infection and drive the infectious cycle. Charting the infectome provides information on the viral biology by the identification of host cell proteins involved in viral infection and allows the development of novel anti-viral drugs that prevent the viruses from establishing productive infection in cells.

The invention discloses a pigeon pox resisting Chinese medicinal composition, which comprises the following components in portion by weight: 25 to 45 portions of root of kudzuvine, 25 to 45 portions of forsythia, 20 to 35 portions of cimicifuga foetida, 20 to 35 portions of glabrous greenbrier rhizome, 20 to 35 portions of dianthus superbus, 15 to 30 portions of honeysuckle, and 15 to 30 portions of liquorice. The invention also discloses a method for preparing oral liquid of the Chinese medicinal composition for resisting the pigeon pox. The Chinese medicament replaced for western medicine is used for treating virus infection of the pigeon pox, and can reduce or eliminate medicament residues in poultry and eggs so that the Chinese medicinal composition is favorable for pollution-free production of animal products, and can be widely applied to pox virus infection of various birds comprising pigeons; after the pigeons suffer from the pox virus infection, the product can treat, so remarkable curative effect can be obtained, and the healing rate reaches more than 95 percent; and in particular for the produced smallpox scabs, the smallpox scabs can fall and heal after medication for one week and do not relapse.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.

The invention discloses a Muscovy duck parvovirus VP3 genetic recombination fowl pox virus transfer vector and a building method thereof. The method includes: fowl pox virus genome is used as the template to amplify the homologous recombination arms TKL and TKR of TK genes, the TKL and TKR are connected into a TK fragment with multiple cloning sites (MCS), and the TK fragment is connected into a framework plasmid to obtain the plasmid pTK; a reverse serial connection expression box S is synthesized and inserted into the plasmid pTK to obtain the plasmid pTKS; VP3 genes are inserted into an MSC1 position behind an early promotor P7.5, and EGFP BGH pA is inserted into an MCS2 position behind a late promotor P11 to obtain the target transfer vector pTKS-VP3-EGFP. After the pTKS-VP3-EGFP transfects chicken embryonic fibroblast infected by the fowl pox virus, RT-PCR and fluorescent protein detection show that VP3 can be expressed normally. By the Muscovy duck parvovirus VP3 genetic recombination fowl pox virus transfer vector and the building method thereof, a foundation is laid on the further development of safe and efficient MDPV recombinant fowl pox virus vaccines.

The invention discloses a preparation method of a chicken pox virus antibody, belonging to the technical field of biology. The method comprises the following steps: (1) culturing the chicken pox virus, and preparing a coarse antigen; (2) preparing the concentrated and purified antigen; (3) preparing the animal immune and antiserum; and (4) purifying the antibody. The antibody prepared by the method disclosed by the invention has the advantages of high purity and favorable specificity, and can be widely used for preparing reagents for detecting chicken pox virus infection.

The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.

The invention provides a fluorescence polarization (FP)-based assay to identify inhibitors of resolvase's DNA cleavage activity. The invention also provides resolvase inhibitors identified by the assay, as well as derivatives and analogs thereof. In certain embodiments, the compounds of the invention are useful to treat a poxvirus infection in an infected subject.

The invention discloses a hybridoma cell line capable of secreting an anti-sheeppox virus K3L protein C-terminal monoclonal antibody, the anti-sheeppox virus K3L holoprotein monoclonal antibody secreted by the hybridoma cell line as well as application of the hybridoma cell line and the antibody. The preservation number of a hybridoma cell line K3L35 capable of secreting the anti-sheeppox virus K3L protein C-terminal monoclonal antibody in China Center for Type Culture Collection (CCTCC) is CCTCC NO: C2015223. The K3L protein C-terminal monoclonal antibody can be secreted by the hybridoma cell line K3L35. The hybridoma cell line K3L35 and the monoclonal antibody secreted by the hybridoma cell line K3L35 can be applied in preparation of a reagent for diagnosing or detecting sheeppox virus infection or a reagent for experiments.

This invention provides compounds of formulas (I), (II), (III), and (IV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a poxvirus infection in a subject using the compounds or compositions.

The invention discloses a preparation for inhibiting poxvirus infections and provides an application of the preparation to the following example (1) or (2): (1) preparation of a product for inhibiting the poxvirus infections; (2) inhibition of the poxvirus infections; the preparation is mainly prepared by mixing epigallocatechin gallate, tannin and astragalus polysaccharides in the mass ratio being (0.5-1.0):(0.5-1.0):(0.5-1.5). The cytotoxicity of the compound formula preparation is not higher than that of control sample ribavirin already having the security permission, and the preparation is safer. Under the condition of safe use concentration, the poxvirus infections can be effectively inhibited by preventively using the preparation, and the preparation has the commercial value in being further developed into a poxvirus infection inhibitor.

The present invention discloses a bioactive preparation specific against variola virus infection model strains and applications thereof. The application provided by the present invention specifically is the use of bioactive preparation CH2009 in following (1) or (2): (1) preparing the products for inhibiting poxvirus infection; or (2) using for inhibiting poxvirus infection. Bioactive preparation CH2009 is a bioactive preparation specific against poxvirus infection prepared and obtained from inflammatory skin tissues by intradermal vaccination of New Zealand white rabbit with vaccinia virus, and through the steps such as high temperature and pressure, solvent extraction, acid-base treatment, adsorption, elution, concentration by centrifugation and others. The present invention provides a completely new design strategy for the development of new generation of drugs against poxviridae infection such as smallpox and others, and it is no doubt that the resultant antiviral drugs have a wide application prospect and a huge commercial value.